FET fusion oncoproteins disrupt physiologic DNA repair and create a targetable opportunity for ATR inhibitor therapy

Shruti Menon(Memorial Sloan Kettering Cancer Center), Asmin Tulpule(Memorial Sloan Kettering Cancer Center)
bioRxiv (Cold Spring Harbor Laboratory)
May 1, 2023
10.1101/2023.04.30.538578
Cited by 5

Related Papers

Temporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation: A Population-based Study
|American Journal of Respiratory and Critical Care Medicine|2023|79
Factors associated with non-fatal heart failure and atrial fibrillation or flutter within the first 30 days post COPD exacerbation: a nested case-control study
|BMC Pulmonary Medicine|2024|3
S86 Factors associated with non-fatal atrial fibrillation or flutter within the first 30 days post-exacerbation of COPD: a nested case-control study
|Unknown|2023|0
Factors associated with non-fatal heart failure and atrial fibrillation or flutter within the first 30 days post COPD exacerbation: a nested case-control study
|Research Square|2024|0
FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
|Cancer Research|2026|0